Kenvue (NYSE:KVUE) Unveils Neutrogena Sunscreen Collaboration With John Cena And New Initiatives

Kenvue (NYSE:KVUE) recently launched the Neutrogena® Ultra Sheer® Face Liquid Mineral Sunscreen SPF 70, supported by a campaign featuring John Cena, emphasizing its commitment to sun safety and innovation. This effort likely played a role in Kenvue's 11% share price increase over the last quarter, despite a challenging macroeconomic landscape, where major indexes like the S&P 500 and Nasdaq saw significant declines due to tariff-related concerns and economic uncertainties. Additionally, investor activism, including TOMS Capital Management acquiring a stake and advocating changes, may have influenced Kenvue’s share performance during this period.

Be aware that Kenvue is showing 4 weaknesses in our investment analysis and 1 of those shouldn't be ignored.

AI is about to change healthcare. These 24 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Over the past year, Kenvue achieved a total shareholder return of 16.04%, reflecting strong performance despite broader market and industry challenges. Kenvue outpaced the US Personal Products industry, which saw a return of -33% over the same period. This performance can be partly attributed to its strategic cost-cutting measures aimed at generating US$350 million in savings by 2026, enhancing its ability to invest in brand growth and innovations. Further bolstering investor confidence was Kenvue's increase in quarterly dividends announced in July 2024 and the subsequent declaration in January 2025, offering a consistent return to shareholders.

Additionally, financial activities such as a share repurchase program in February 2025 demonstrated Kenvue's commitment to enhancing shareholder value. However, challenges, such as a reported net income of US$1.03 billion for 2024, down from US$1.664 billion, along with operational impacts from its separation from Johnson & Johnson, highlighted the company's adaptive strategies in an evolving macroeconomic environment.

In light of our recent valuation report, it seems possible that Kenvue is trading beyond its estimated value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com